The deal covers a diverse portfolio of eight generic injectables, for which abbreviated new drug applications (ANDAs) have already been filed and are pending approval or for which the ANDAs will be filed imminently. Combined sales for both branded and generic versions of the products in the US are estimated to be approximately US$1 billion for the 12 months ending in August 2016, according to IMS Health.

Dr Reddy’s Executive Vice-President and Head of North America Alok Sonig said the deal with Gland would complement the company’s specialty injectables offering in the short-to-medium term.

Gland Pharma Chief Operating Officer Srinivas Sadu said the company was happy to expand its collaboration with Dr Reddy’s, which he said has an ‘impressive track record of commercialising injectables products in the US’.

Dr Reddy’s also stated that it ‘is developing its injectable business in the US and recently launched paricalcitol injection, a therapeutically equivalent generic version of Zemplar (paricalcitol injection) there’.

Related articles
Dr Reddy’s expands collaboration with Amgen in India

Dr Reddy’s to buy US generics from Teva

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.